Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00033425.xml
Download PDF
CC BY-NC-ND 4.0 · Revista Chilena de Ortopedia y Traumatología 2021; 62(02): e136-e142
DOI: 10.1055/s-0041-1735295
DOI: 10.1055/s-0041-1735295
Artículo de Revisión | Review Article
Manejo actual de las metástasis vertebrales: un trabajo en equipo
Article in several languages: español | English
Resumen
La enfermedad metastásica vertebral es frecuente en los pacientes con cáncer avanzado, y conlleva a complicaciones inherentes a su progresión, como lo son la fractura patológica vertebral y la compresión neural metastásica. Se realizó una revisión de los aspectos terapéuticos actuales del manejo de la progresión y de las complicaciones de la enfermedad metastásica vertebral, enfatizando su enfrentamiento sistémico y personalizado. Nuestro objetivo principal es proporcionar información sobre el tratamiento actual de esta afección y la utilidad del manejo sistémico y multidisciplinario.
Publication History
Received: 05 July 2020
Accepted: 31 March 2021
Article published online:
30 September 2021
© 2021. Sociedad Chilena de Ortopedia y Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referencias
- 1 Joaquim AF, Powers A, Laufer I, Bilsky MH. An update in the management of spinal metastases. Arq Neuropsiquiatr 2015; 73 (09) 795-802
- 2 Klimo Jr P, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004; 9 (02) 188-196
- 3 Falkner U. Järhult J, Wersäll P, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol (Madr) 2003; 42 (5–6): 620-633
- 4 Bilsky M, Smith M. Surgical approach to epidural spinal cord compression. Hematol Oncol Clin North Am 2006; 20 (06) 1307-1317
- 5 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (01) 5-29
- 6 Perou CM, Sørlie T, Eisen MB. et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747-752
- 7 Lee IH. Molecular Prognostic and Predictive Assays in Breast Cancer: A Practical Review. AJSP: Reviews & Reports 2016; 21 (01) 4-10
- 8 Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982; 28 (04) 865-871
- 9 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16) 1659-1672
- 10 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11) 783-792
- 11 Swain SM, Baselga J, Kim SB. et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372 (08) 724-734
- 12 Verma S, Miles D, Gianni L. et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367 (19) 1783-1791
- 13 Geyer CE, Forster J, Lindquist D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 (26) 2733-2743
- 14 Davies C, Godwin J, Gray R. et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378 (9793): 771-784
- 15 Chia SK, Speers CH, D'yachkova Y. et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110 (05) 973-979
- 16 Cristofanilli M, Turner NC, Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17 (04) 425-439
- 17 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66 (01) 7-30
- 18 NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26 (28) 4617-4625
- 19 Lee CK, Brown C, Gralla RJ. et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105 (09) 595-605
- 20 Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373 (02) 123-135
- 21 Borghaei H, Paz-Ares L, Horn L. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373 (17) 1627-1639
- 22 Herbst RS, Baas P, Kim DW. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027): 1540-1550
- 23 Antonia SJ, Villegas A, Daniel D. et al; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377 (20) 1919-1929
- 24 Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56 (06) 1021-1024
- 25 Seidenfeld J, Samson DJ, Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132 (07) 566-577
- 26 Crawford ED, Eisenberger MA, McLeod DG. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321 (07) 419-424
- 27 Scher HI, Fizazi K, Saad F. et al; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13) 1187-1197
- 28 de Bono JS, Logothetis CJ, Molina A. et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21) 1995-2005
- 29 Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26 (02) 242-245
- 30 de Bono JS, Oudard S, Ozguroglu M. et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154
- 31 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373 (08) 737-746
- 32 Fizazi K, Tran N, Fein L. et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377 (04) 352-360
- 33 Laufer I, Rubin DG, Lis E. et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013; 18 (06) 744-751
- 34 Hortobagyi GN, Theriault RL, Porter L. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335 (24) 1785-1791
- 35 Kohno N, Aogi K, Minami H. et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23 (15) 3314-3321
- 36 Stopeck AT, Lipton A, Body JJ. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28 (35) 5132-5139
- 37 Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; (02) CD003474 . Doi: 10.1002/14651858.cd003474.pub3
- 38 Bilsky MH, Laufer I, Fourney DR. et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 2010; 13 (03) 324-328
- 39 Fisher CG, DiPaola CP, Ryken TC. et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 2010; 35 (22) E1221-E1229
- 40 Bate BG, Khan NR, Kimball BY, Gabrick K, Weaver J. Stereotactic radiosurgery for spinal metastases with or without separation surgery. J Neurosurg Spine 2015; 22 (04) 409-415
- 41 Lo SS, Sahgal A, Chang EL. Major Complications Associated with Stereotactic Ablative Radiotherapy for Spinal Metastasis. In: AOSPine Masters Series Metastatic Spinal Tumors. 1st Ed. New York: Thieme Medical Publishers, Inc.; 2015: 23-33
- 42 Patchell RA, Tibbs PA, Regine WF. et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486): 643-648
- 43 Hulme PA, Krebs J, Ferguson SJ, Berlemann U. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine 2006; 31 (17) 1983-2001
- 44 Kassamali RH, Ganeshan A, Hoey ETD, Crowe PM, Douis H, Henderson J. Pain management in spinal metastases: the role of percutaneous vertebral augmentation. Ann Oncol 2011; 22 (04) 782-786
- 45 Wise JJ, Fischgrund JS, Herkowitz HN, Montgomery D, Kurz LT. Complication, survival rates, and risk factors of surgery for metastatic disease of the spine. Spine 1999; 24 (18) 1943-1951
- 46 Lee RS, Batke J, Weir L, Dea N, Fisher CG. Timing of surgery and radiotherapy in the management of metastatic spine disease: expert opinion. J Spine Surg 2018; 4 (02) 368-373
- 47 Barzilai O, McLaughlin L, Amato MK. et al. Minimal Access Surgery for Spinal Metastases: Prospective Evaluation of a Treatment Algorithm Using Patient-Reported Outcomes. World Neurosurg 2018; 120: e889-e901
- 48 Laufer I, Iorgulescu JB, Chapman T. et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 2013; 18 (03) 207-214
- 49 Schwab JH, Gasbarrini A, Cappuccio M. et al. Minimally Invasive Posterior Stabilization Improved Ambulation and Pain Scores in Patients with Plasmacytomas and/or Metastases of the Spine. Int J Surg Oncol 2011; 2011: 239230 . Doi: 10.1155/2011/239230
- 50 Donnelly DJ, Abd-El-Barr MM, Lu Y. Minimally Invasive Muscle Sparing Posterior-Only Approach for Lumbar Circumferential Decompression and Stabilization to Treat Spine Metastasis–Technical Report. World Neurosurg 2015; 84 (05) 1484-1490